Ad-hoc-release pursuant to Art. 17 MAR
European Commission extends Ameluz® approval to basal cell carcinomaLeverkusen, Germany, January 30, 2017 - Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, announces today that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has granted approval extension for Ameluz® to basal cell carcinoma. The extended approval includes the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.
The Management Board
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen ISIN: DE0006046113
WKN: 604611
contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com
page 1
Biofrontera AG published this content on 30 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 January 2017 15:54:19 UTC.
Original documenthttp://biofrontera.com/en/investors/ad-hoc-news.html?file=tl_files/documents/adhoc-news/2017/20170130 ad hoc BCC Zulassung_EN.pdf
Public permalinkhttp://www.publicnow.com/view/F03E20057D6901D9A7084F95A4B07F0684ECF760